These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34627297)

  • 1. A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine.
    Sabbaghi A; Malek M; Abdolahi S; Miri SM; Alizadeh L; Samadi M; Mohebbi SR; Ghaemi A
    Virol J; 2021 Oct; 18(1):201. PubMed ID: 34627297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A
    Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs.
    Dhakal S; Cheng X; Salcido J; Renu S; Bondra K; Lakshmanappa YS; Misch C; Ghimire S; Feliciano-Ruiz N; Hogshead B; Krakowka S; Carson K; McDonough J; Lee CW; Renukaradhya GJ
    Int J Nanomedicine; 2018; 13():6699-6715. PubMed ID: 30425484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.
    Wong PT; Goff PH; Sun RJ; Ruge MJ; Ermler ME; Sebring A; O'Konek JJ; Landers JJ; Janczak KW; Sun W; Baker JR
    Mol Pharm; 2021 Feb; 18(2):679-698. PubMed ID: 32491861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.
    Thomas M; Wang Z; Sreenivasan CC; Hause BM; Gourapura J Renukaradhya ; Li F; Francis DH; Kaushik RS; Khatri M
    Vaccine; 2015 Jan; 33(4):542-8. PubMed ID: 25437101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
    Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
    J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
    Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.